FDA Clears OncoMed Pharmaceuticals, Inc.'s Demcizumab (Anti-DLL4) to Resume Clinical Testing in the U.S.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--OncoMed Pharmaceuticals, a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the U.S. Food and Drug Administration (FDA) has removed a partial clinical hold on its demcizumab (OMP-21M18) clinical program. Demcizumab is a humanized monoclonal antibody that targets Delta Like Ligand 4, or DLL4, in the Notch signaling pathway. Jakob Dupont, MD, OncoMed’s Chief Medical Officer, stated, “We are pleased that the FDA has responded favorably to the demcizumab clinical data and development strategy and removed the partial clinical hold to allow further development of demcizumab in the United States.”